Screener
Bioventus BVS Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total Net Sales by Business | ||||||
| International Segment | $18.74M-0.8% | $15.64M+17.1% | $18.41M-0.1% | $15.34M-4.5% | $18.89M+12.4% | |
| U.S. Segment | $134.47M+4.4% | $116.45M+5.4% | $139.49M+3.2% | $123.31M+0.3% | $128.78M-4.2% | |
| Total Net Sales by Product | ||||||
| Pain Treatments | $81.75M+11.5% | $63.43M+7.7% | $79.66M+15.1% | $67.18M+6.4% | $73.31M+1.5% | |
| Restorative Therapies | $21.11M-2.4% | $20.64M+4.6% | $22.71M-26.0% | $21.31M-28.8% | $21.64M-31.6% | |
| Surgical Solutions | $50.35M-4.5% | $48.03M+6.2% | $55.53M+3.4% | $50.17M+9.3% | $52.72M+11.4% | |
| Total Net Sales by Geography | ||||||
| International | $18.74M-0.8% | $15.64M+17.1% | $18.41M-0.1% | $15.34M-4.5% | $18.89M+12.4% | |
| U.S. | $134.47M+4.4% | $116.45M+5.4% | $139.49M+3.2% | $123.31M+0.3% | $128.78M-4.2% |
FAQ
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
